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1. INTRODUCTION {#jcmm15347-sec-0001}
===============

With the progress of medical technology and the extension of human life expectancy, non‐communicable diseases have become the main cause of threats to human life, especially the cancers.[^1^](#jcmm15347-bib-0001){ref-type="ref"} It is estimated that there were more than 18.1 million new cancer cases and 9.6 million deaths worldwide in 2018.[^1^](#jcmm15347-bib-0001){ref-type="ref"}, [^2^](#jcmm15347-bib-0002){ref-type="ref"} Precise biomarkers are believed to be of great important for cancer diagnosis and therapy but currently remain great limited. Recently, the accumulated big omics‐data provides great opportunities for exploring cancer biomarkers, however, the biomarkers found by this data‐driven strategy often do not work well on new datasets.[^3^](#jcmm15347-bib-0003){ref-type="ref"} Currently, although some biomarkers have been discovered and applied in the diagnosis, treatment and prognosis of cancers,[^4^](#jcmm15347-bib-0004){ref-type="ref"}, [^5^](#jcmm15347-bib-0005){ref-type="ref"}, [^6^](#jcmm15347-bib-0006){ref-type="ref"} due to the heterogeneity and diversity of diseases, the deficiency of efficient biomarkers represents one of the main bottlenecks limiting cancer medicine.[^7^](#jcmm15347-bib-0007){ref-type="ref"}, [^8^](#jcmm15347-bib-0008){ref-type="ref"} In order to diagnose and treat effectively, extend the survival time and improve the prognosis, there is an urgent need for universal and effective diagnosis and prognostic evaluation biomarkers.

Atavism is considered as a reappearance of lost progenitor phenotype in genetics.[^9^](#jcmm15347-bib-0009){ref-type="ref"} In the last decade, the hypothesis that cancer is an atavistic condition was proposed, which holds that the genes related to cell cooperation that evolved into multicellular organisms about 1 billion years ago match the genes that cause cancer. This \'unlock of ancient toolkit\' leads to the occurrence of cancer.[^10^](#jcmm15347-bib-0010){ref-type="ref"} Cancer cells are moulded into protozoan‐like organisms whose original specific functions and characteristics disappear and become purely for survival.[^11^](#jcmm15347-bib-0011){ref-type="ref"} Another study pointed out that in the process of drug resistance of tumours, in addition to the accumulation of somatic mutations, which is the traditional view of the occurrence of cancer, there is also the regulation of some non‐mutated genes, which is very ancient and conservative and may be the basis of life.[^12^](#jcmm15347-bib-0012){ref-type="ref"} Thus, atavistic model can be combined with somatic selection model as a new explanation for the occurrence and development of cancer.[^13^](#jcmm15347-bib-0013){ref-type="ref"}

Given the above observation, we have been suggested that progenitor genes might serve as biomarkers for cancer. To confirm this hypothesis, we first curated 77 progenitor genes according to the phyletic age and the essentiality of genes from the database of Online Gene Essentiality (OGEE).[^14^](#jcmm15347-bib-0014){ref-type="ref"}, [^15^](#jcmm15347-bib-0015){ref-type="ref"} Then we proposed a score to quantify the progenitorness of a sample using its expression profile data. By applying progenitorness score to 33 types of cancers of 81 datasets from the Cancer Genome Atlas (TCGA), the Chinese Glioma Genome Atlas (CGGA), the Gene Expression Omnibus (GEO) and the Integrative Molecular Database of Hepatocellular Carcinoma (HCCDB)[^16^](#jcmm15347-bib-0016){ref-type="ref"} databases, we showed that the proposed progenitorness score work efficiently for the diagnosis, prognosis, grading and monitoring therapy of various cancers.

2. MATERIALS AND METHODS {#jcmm15347-sec-0002}
========================

2.1. Curation of progenitor genes and single‐sample gene set enrichment analysis {#jcmm15347-sec-0003}
--------------------------------------------------------------------------------

Given that this study is based on the atavism hypothesis of cancer, here we aim to investigate whether ancient progenitor genes can be used as cancer biomarkers. The database of Online Gene Essentiality (OGEE, <http://ogee.medgenius.info/browse/>) defines the phyletic age and the essentiality of genes. Six different phyletic ages for the genes were defined from ancient to present: cellular organisms, Eukaryota, Fungi/Metazoa group, Metazoa, Chordata and Mammalia. We define the progenitor genes as essential genes whose phyletic ages are cellular organisms or Eukaryota. As a result, we curated a total of 77 progenitor genes (File S1). To calculate the progenitorness score, we perform single‐sample gene set enrichment analysis[^17^](#jcmm15347-bib-0017){ref-type="ref"} (ssGSEA) of gene expression profiles in the progenitor gene set by python (v3.6.8) package gseapy (v0.9.16), which is a python wrapper for GSEA and ssGSEA.

2.2. Data collection and pre‐processing {#jcmm15347-sec-0004}
---------------------------------------

TCGA RNA sequencing (RNAseq) data in fragments per kilobase of transcript per million mapped reads (FPKM) and clinical information were downloaded from GDC data portal (<https://portal.gdc.cancer.gov/>). Histology type and WHO grade of TCGA lower grade glioma (LGG) and glioblastoma multiforme (GBM) were obtained from the study by Ceccarelli et al[^18^](#jcmm15347-bib-0018){ref-type="ref"} CGGA (<http://www.cgga.org.cn/>) contains gene expression and clinical data of more than 1000 patients with glioma, which are separated into one microarray and two RNAseq batches, giving researchers an opportunity to delve deeper into glioma. HCCDB[^16^](#jcmm15347-bib-0016){ref-type="ref"} (<http://lifeome.net/database/hccdb/home.html>) provides 15 public hepatocellular carcinoma (HCC) gene expression matrices from TCGA, the International Cancer Genome Consortium (ICGC) and GEO datasets, which were processed in a unified process. HCC proteome data were obtained from Gao et al[^19^](#jcmm15347-bib-0019){ref-type="ref"} In addition, microarray gene expression profiling data and RNAseq data were collected from GEO database (<https://www.ncbi.nlm.nih.gov/gds/>). Cancer Cell Line Encyclopedia[^20^](#jcmm15347-bib-0020){ref-type="ref"} (CCLE, <https://portals.broadinstitute.org/ccle/>) provides RNAseq data for thousands of cancer cell lines. Gene expression data were structured with gene symbols as row names, sample ids as column names, duplicate gene symbols were dropped except their max value. Drug sensitivity data are available from Cancer Therapeutics Response Portal[^21^](#jcmm15347-bib-0021){ref-type="ref"} (CTRP, <http://portals.broadinstitute.org/ctrp/)and> Genomics of Drug Sensitivity in Cancer[^22^](#jcmm15347-bib-0022){ref-type="ref"} (GDSC, <https://www.cancerrxgene.org/>).

2.3. Statistical Analysis {#jcmm15347-sec-0005}
-------------------------

All statistical significances were calculated by R (v3.5.2). Cox proportional hazards regression and Kaplan‐Meier (K‐M) curves were processed by R package survival (v3.1‐7) and survminer (v0.4.6). Log‐rank test was used to evaluate the difference between two K‐M curves. Receiver operating characteristic (ROC) curve and area under ROC curve (AUROC) were performed by R package pROC[^23^](#jcmm15347-bib-0023){ref-type="ref"} (v1.15.3). Significance of difference between two groups of continuous variables was calculated by two‐side Wilcoxon rank‐sum test. Differences of paired samples were evaluated by Wilcoxon signed‐rank test. Spearman\'s tests were used to estimate correlation between two continuous variables. The *P* values of Spearman\'s test were adjusted using R package fdrtool (v1.2.15).

3. RESULTS {#jcmm15347-sec-0006}
==========

3.1. Progenitorness score distinguishes tumours from normal samples {#jcmm15347-sec-0007}
-------------------------------------------------------------------

Firstly, we investigated whether the proposed progenitorness score is able to distinguish tumour samples from normal samples. As expected, primary tumours showed significantly higher progenitorness scores than normal tissues for all 17 types of cancers in the TCGA database (Figure [1A](#jcmm15347-fig-0001){ref-type="fig"}). Moreover, progenitorness score showed a good prediction performance in distinguishing tumours from normal samples (Figure [1B](#jcmm15347-fig-0001){ref-type="fig"}). We obtained similarity results in datasets from GEO and HCCDB (Figure [1C](#jcmm15347-fig-0001){ref-type="fig"}, Figure S1, S2). We noted that progenitorness score did not work well on only one dataset ([GSE46444](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE46444)), which could be resulted from the fact that the samples of this dataset were formalin‐fixed paraffin‐embedded (AS‐FFPE). In addition, the [GSE25097](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE25097) dataset has samples of cirrhotic liver. As expected, the progenitorness scores of cirrhotic livers are between those from the cancer samples and those from the adjacent samples (Figure [S2](#jcmm15347-sup-0001){ref-type="supplementary-material"}E, I).

![Progenitorness score distinguishes tumours from normal samples. A, Distribution of progenitorness score in different cancer types and sample types in TCGA. Significances of difference between primary tumours and normal tissues were analysed by two‐side Wilcoxon rank‐sum test. \*\*\**P* \< 0.001. B, ROC curves of progenitorness scores discriminating primary tumours from normal tissues in TCGA. (C) ROC curves of progenitorness scores discriminating primary tumours from normal tissues in HCCDB. The area under ROC curves are shown in parentheses. The cancer type abbreviations of TCGA is in [https://gdc.cancer.gov/resources‐tcga‐users/tcga‐code‐tables/tcga‐study‐abbreviations](https://gdc.cancer.gov/resources-tcga-users/tcga-code-tables/tcga-study-abbreviations)](JCMM-24-6908-g001){#jcmm15347-fig-0001}

3.2. Progenitorness score predicts the survival of cancer patients {#jcmm15347-sec-0008}
------------------------------------------------------------------

Survival analysis found that higher progenitorness score indicates shorter survival time in various cancers in TCGA (Figure [2A](#jcmm15347-fig-0002){ref-type="fig"}; Figure [S3](#jcmm15347-sup-0001){ref-type="supplementary-material"}). Meanwhile, 16 datasets of 7 types of cancers with survival information were collected from CGGA, HCCDB and GEO datasets. K‐M curves showed that patients with higher progenitorness scores had shorter overall/recurrent‐free/disease‐free survival time (Figure [2B](#jcmm15347-fig-0002){ref-type="fig"}‐G; Figure [S4](#jcmm15347-sup-0001){ref-type="supplementary-material"}). Cox regression also confirmed that progenitorness score was an effective prognostic risk factor in survival (Tables [1](#jcmm15347-tbl-0001){ref-type="table"} and [2](#jcmm15347-tbl-0002){ref-type="table"}). After being adjusted with age, gender, histology and WHO grade, progenitorness score was demonstrated to be an independent risk factor for glioma (Table [1](#jcmm15347-tbl-0001){ref-type="table"}).

![Progenitorness score predicts the survival of cancer patients. A, Analysis between progenitorness score and survival of different cancer types in TCGA, ln(hazard ratio) and 95% confidence interval (95% CI) of progenitorness score using Cox proportional hazards regression models were shown. 95% CI that does not include zero is considered significant. (B‐G) Kaplan‐Meier curve of survival in different tumour gene expression datasets. Group was separated by the median value of progenitorness scores. Differences between two curves were estimated by log‐rank test. B, CGGA RNAseq batch 2. C, Liver Cancer -- RIKEN, Japan Project from International Cancer Genome Consortium, processed by HCCDB. D, [GSE25066](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE25066) breast cancer. E, [GSE30219](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE30219) lung cancer. F, [GSE32918](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32918) lymphoma. G, [GSE13876](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13876) ovarian cancer](JCMM-24-6908-g002){#jcmm15347-fig-0002}

###### 

The predictive ability on survival time of progenitorness score adjusted using age, gender, WHO grade and histology

  Datasets                                                                     Unadjusted   Adjusted                                                                                                
  ---------------------------------------------------------------------------- ------------ -------------------------------------------- ---------------- ----- ----------------------------------- ---------------
  CGGA Microarray                                                              298          43.6 (11.9‐160)                              1.23 × 10^−8^    293   3.11 (0.766‐12.7)                   0.112
  CGGA RNAseq batch 1                                                          311          3.85 × 10^9^(3.67 × 10^7^‐4.04 × 10^11^)     1.47 × 10^−20^   307   31 800 (126‐8.02 × 10^6^)           2.38 × 10^−4^
  CGGA RNAseq batch 2                                                          619          8.57 × 10^7^ (3.08 × 10^6^‐2.38 × 10^9^)     5.04 × 10^−27^   618   1.63 × 10^5^ (3420‐7.77 × 10^6^)    1.15 × 10^−9^
  TCGA GBM + LGG                                                               695          4.04 × 10^20^ (1.5 × 10^17^‐1.09 × 10^24^)   5.48 × 10^−32^   634   2.14 × 10^8^ (2610‐1.75 × 10^13^)   8.92 × 10^−4^
  [GSE4412](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4412)‐GPL96   85           1.19 × 10^5^ (23.2‐6.14 × 10^8^)             0.00733          85    391 (0.0333‐4.59 × 10^6^)           0.212

Hazard ratio (HR) and 95% confidence interval (95% CI) of progenitorness score using univariate and multivariate Cox proportional hazards regression models for gliomas were shown. HR with 95% CI that does not include one is considered significant.

John Wiley & Sons, Ltd

###### 

The predictive ability on survival time of progenitorness score in several types of cancers

  Datasets                                                                 Cancer type   Survival type   n     HR (95% CI)                                  *P*
  ------------------------------------------------------------------------ ------------- --------------- ----- -------------------------------------------- ----------------
  HCCDB ICGC‐LIRI‐JP                                                       Liver         OS              212   3.07 × 10^14^ (2.61 × 10^8^‐3.59 × 10^20^)   2.89 × 10^−6^
  HCCDB TCGA‐HCC                                                           Liver         OS              351   9.35 × 10^7^ (77 500‐1.13 × 10^11^)          3.99 × 10^−7^
  [GSE25066](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE25066)   Breast        DRFS            508   3600 (9.62‐1.35 × 10^6^)                     0.00675
  [GSE32603](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32603)   Breast        RFS             248   119 (10.1‐1410)                              1.48 × 10^−4^
  [GSE30219](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE30219)   Lung          OS              293   7.95 × 10^6^ (75 300‐8.38 × 10^8^)           2.33 × 10^−11^
  [GSE30219](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE30219)   Lung          DFS             278   2.83 × 10^8^ (4.11 × 10^5^‐1.95 × 10^11^)    5.32 × 10^−9^
  [GSE37745](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE37745)   Lung          OS              196   1510 (2.82‐8.06 × 10^5^)                     0.0224
  [GSE41271](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41271)   Lung          OS              274   2.42 × 10^7^ (398‐1.47 × 10^12^)             0.00249
  [GSE41271](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41271)   Lung          RFS             274   1.09 × 10^6^ (18.5‐6.38 × 10^10^)            0.0131
  [GSE42127](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE42127)   Lung          OS              176   5.59 × 10^7^ (5.52‐5.65 × 10^14^)            0.0302
  [GSE50081](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50081)   Lung          OS              181   4430 (1.52‐1.29 × 10^7^)                     0.0391
  [GSE32918](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32918)   Lymph         OS              249   2.20 × 10^5^ (87‐5.58 × 10^8^)               0.00209
  [GSE13876](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13876)   Ovary         OS              415   82 (1.93‐3490)                               0.0213
  [GSE62452](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE62452)   Pancreas      OS              65    2.39 × 10^7^ (361‐1.59 × 10^12^)             0.00271

Abbreviations: DFS, disease‐free survival; DRFS, distance recurrence‐free survival; OS, overall survival; RFS, recurrence‐free survival.

Hazard ratio (HR) and 95% confidence interval (95% CI) of progenitorness score using univariate Cox proportional hazards regression models were shown. HR with 95% CI that does not include one is considered significant.
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3.3. Progenitorness score indicates tumour grades {#jcmm15347-sec-0009}
-------------------------------------------------

We first studied the relationship between progenitorness score and WHO grade of glioma and found that cancers with higher grade had significantly higher progenitorness score in all 12 datasets from TCGA, CGGA and GEO datasets (Figure [3](#jcmm15347-fig-0003){ref-type="fig"}). It is worth mentioning that progenitorness score also shows the ability to distinguish glioma from normal brain tissues (Figure [3E](#jcmm15347-fig-0003){ref-type="fig"}‐G,I; Figure [S5](#jcmm15347-sup-0001){ref-type="supplementary-material"}). It needs to be noted that in other type of cancers, progenitorness score has less impact on the assessment of tumour stage (Figure [S6](#jcmm15347-sup-0001){ref-type="supplementary-material"}).

![Progenitorness score indicates glioma grades. Distribution of progenitorness scores in different grade of gliomas or normal brain tissues. Significances of difference between two groups were analysed by two‐side Wilcoxon rank‐sum test. \**P* \< 0.05, \*\* *P* \< 0.01, \*\*\**P* \< 0.001. A, TCGA lower grade glioma (LGG) and glioblastoma multiforme (GBM). B, CGGA Microarray. C, CGGA RNAseq batch 1. D, CGGA RNAseq batch 2. E, [GSE4290](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4290). F, [GSE7696](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE7696). G, [GSE16011](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16011). H, [GSE35158](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE35158). I, [GSE50161](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50161). J, [GSE52009](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE52009). K, [GSE54004](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54004). L, [GSE61374](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61374)](JCMM-24-6908-g003){#jcmm15347-fig-0003}

3.4. Progenitorness score guides cancer therapy {#jcmm15347-sec-0010}
-----------------------------------------------

From the GEO gene expression data of tumour cell lines treated with various anticancer drugs ([GSE116436](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116436)), we observed a significant decrease of progenitorness score with the increase of drug concentration and the extension of treatment time (Figure [4A](#jcmm15347-fig-0004){ref-type="fig"}; Figure [S7](#jcmm15347-sup-0001){ref-type="supplementary-material"}; Figure [S8](#jcmm15347-sup-0001){ref-type="supplementary-material"}). In addition to cell trials, cancer samples of breast cancer patients also showed a decrease in progenitorness score after treatment (Figure [4B](#jcmm15347-fig-0004){ref-type="fig"}). To further investigate the relationship between progenitorness score and drug response, we collected the sensitivity to anticancer drugs of cell lines from the Cancer Therapeutics Response Portal (CTRP) and the Genomics of Drug Sensitivity in Cancer (GDSC). Area under concentration‐viability curve[^24^](#jcmm15347-bib-0024){ref-type="ref"} (AUC, the higher, the more resistant) is used to calculate the Spearman\'s correlation with progenitorness score. We found that the sensitivity of most drugs was significantly correlated with progenitorness score (FDR \< 0.05) (Figure [4C](#jcmm15347-fig-0004){ref-type="fig"}, File S2). For example, the AUC of Cetuximab and AZD3759, which both are epidermal growth factor receptor (EGFR) inhibitors,[^25^](#jcmm15347-bib-0025){ref-type="ref"}, [^26^](#jcmm15347-bib-0026){ref-type="ref"} were found to have the most significant positive correlation with progenitorness score in two versions of GDSCs separately, which suggest a resistance to EGFR inhibitors for tumours with high progenitorness scores. The above results suggest that progenitorness score could be used to guide drug selection, either predict the efficacy before treatment or evaluate the efficacy after treatment.

![Progenitorness score guides cancer therapy and shows a wider application scenario. A, Variation of progenitorness scores in NCI‐60 cell lines treated with Doxorubicin in different drug concentration and treatment time. B, Distribution of progenitorness scores in breast cancer patients with different treatments. C, Drugs correlated with progenitorness scores in CTRP and two versions of GDSC. D, Progenitorness scores of HCC patients with/without vascular invasion. E, Distribution of progenitorness scores in heart with/without heart failure. F, Number (mean ± sd) of genes detected (read count \> 0) in different datasets. G, Distribution of progenitorness scores in human embryonic stem cells of different culture days. (A, B, D, E, G) Two‐side Wilcoxon rank‐sum test, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. H, Variation of progenitorness scores in an HCC‐normal paired proteome data. Wilcoxon signed‐rank test, \*\*\**P* \< 0.001](JCMM-24-6908-g004){#jcmm15347-fig-0004}

3.5. Progenitorness score shows a wider application scenario {#jcmm15347-sec-0011}
------------------------------------------------------------

Furthermore, progenitorness score showed a significant predictive effect on vascular invasion of HCC (Figure [4D](#jcmm15347-fig-0004){ref-type="fig"}). It is worth mentioning that, in addition to cancer, progenitorness score also showed reasonable results in cardiovascular diseases. For example, we found that the diseased hearts have lower progenitorness scores than the normal hearts (Figure [4E](#jcmm15347-fig-0004){ref-type="fig"}).

Besides microarray and bulk RNA sequencing, single‐cell RNA sequencing (scRNAseq) data and proteome data have been also accumulated rapidly in recent years. Yao et al[^27^](#jcmm15347-bib-0027){ref-type="ref"} studied the differentiation from human embryonic stem cells (hESCs) to early forebrain and mid/hindbrain cells using scRNAseq technique. We downloaded the scRNAseq data ([GSE86977](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE86977)) of hESCs for different culture days during differentiation from GEO datasets and then calculated their progenitorness scores. Although fewer genes were detected in scRNAseq data (Figure [4F](#jcmm15347-fig-0004){ref-type="fig"}), it showed ideal and reasonable evaluation results: progenitorness score decreased significantly with time (Figure [4G](#jcmm15347-fig-0004){ref-type="fig"}). Meanwhile, we asked whether progenitorness score works well on protein expression data. For doing so, we downloaded the proteome data of an HCC‐normal paired study by Gao et al[^19^](#jcmm15347-bib-0019){ref-type="ref"} The result showed that progenitorness score showed significant ability to classify cancer samples from normal tissues (Figures [1C](#jcmm15347-fig-0001){ref-type="fig"} and [4H](#jcmm15347-fig-0004){ref-type="fig"}).

4. DISCUSSION {#jcmm15347-sec-0012}
=============

From the atavism of cancer, we collected 77 essential genes appeared at the age of cellular organisms and eukaryote and proposed the progenitorness score as a biomarker for multi usages of multi cancers. Biomarkers are often difficult to popularize due to different batches, different platforms (microarray, bulk RNAseq, scRNAseq, proteome), different types of cancers and tissues, different processing methods of original data.[^3^](#jcmm15347-bib-0003){ref-type="ref"} But the progenitorness score was validated by dozens of datasets from TCGA, GEO, CGGA and HCCDB, etc Although fewer genes (proteins) were detected, and mRNA can only explain about 40% of the variability of protein,[^28^](#jcmm15347-bib-0028){ref-type="ref"} progenitorness score is robust in scRNAseq and proteome data.

It has been reported that older genes show greater necessity,[^29^](#jcmm15347-bib-0029){ref-type="ref"} we also found this phenomenon (Figure [S9](#jcmm15347-sup-0001){ref-type="supplementary-material"}A). In addition, gene expression at each stage of embryonic development also showed a correlation with gene age.[^30^](#jcmm15347-bib-0030){ref-type="ref"} To further explore the function of gene set that we collected, we performed GO enrichment analysis. The results showed that the genes were enriched on functions about protein degradation, DNA replication and cell cycle (Figure [S9](#jcmm15347-sup-0001){ref-type="supplementary-material"}B). These results may be due to a common characteristic of ancestral organisms, embryos and cancers: rapid proliferation, which partly explains why progenitorness score is effective in a wide variety of tumours. However, it needs to be pointed out that our progenitorness gene set has no intersection with stemness gene set in the Kyoto Encyclopedia of Genes and Genomes[^31^](#jcmm15347-bib-0031){ref-type="ref"} (KEGG, pathway id: hsa04550) and PathCards,[^32^](#jcmm15347-bib-0032){ref-type="ref"} which reveals a new perspective on cancer progression.

We also tried to reduce the gene set and optimize it for various tissue types separately. RNA sequencing data for different tissues from the Genotype‐Tissue Expression (GTEx)[^33^](#jcmm15347-bib-0033){ref-type="ref"} database have been downloaded and the specificities of each progenitor gene in various tissues were calculated. We then applied the specific gene sets to TCGA cancers of the corresponding tissues. However, the diagnostic and prognostic abilities of these gene sets were not increased, comparing with the original 77 genes (data not shown).

An interesting phenomenon is that in rectum adenocarcinoma (READ) of TCGA, progenitorness score shows a negative correlation with survival (HR = 3.00 × 10^−28^, *P* = 0.0199). At the same time, stomach adenocarcinoma (STAD) showed the same but not significant trend (HR = 4.44 × 10^−5^, *P* = 0.147). Similar results were observed in the analysis of colorectal and gastric cancer data from GEO datasets (Figure [S10](#jcmm15347-sup-0001){ref-type="supplementary-material"}), which were probably not by accident. The reason is worth further validating and exploring.

In summary, to explore the atavism of cancer, we have been suggested that ancient genes could serve as a biomarker of cancer. As a result, 77 progenitor genes were collected and applied to calculate progenitorness score. After the verification of dozens of cancer gene expression data, progenitorness score has been found to be used for the diagnosis, prognosis, grading, medication guidance and other purposes of a variety of cancers. Furthermore, we revealed the possible role of ancient genes in the development of cancer and showed an atavistic landscape of cancer.
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